Skip to main content
SpringerLink
Log in

Liver Cancer

  • Chapter
  • First Online:
Gastrointestinal Oncology

Abstract

This chapter provides extensive background on the etiology, risk factors, and epidemiology of hepatocellular carcinoma. The various staging and prognostic systems, patient evaluation guidelines, and evidence-based description of all treatment options, are included.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A et al (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24(26):4293–4300

    Article  CAS  PubMed  Google Scholar 

  • Anna CH, Maronpot RR, Pereira MA, Foley JF, Malarkey DE, Anderson MW (1994) ras proto-oncogene activation in dichloroacetic acid-, trichloroethylene- and tetrachloroethylene-induced liver tumors in B6C3F1 mice. Carcinogenesis 15(10):2255–2261

    Article  CAS  PubMed  Google Scholar 

  • Befeler AS, Di Bisceglie AM (2002) Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 122(6):1609–1619

    Article  PubMed  Google Scholar 

  • Belghiti J, Cortes A, Abdalla EK, Regimbeau JM, Prakash K, Durand F et al (2003) Resection prior to liver transplantation for hepatocellular carcinoma. Ann Surg 238(6):885–892; discussion 892–893

    Google Scholar 

  • Bialecki ES, Di Bisceglie AM (2005) Clinical presentation and natural course of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 17(5):485–489

    Article  PubMed  Google Scholar 

  • Bismuth H (2000) Multimodal therapy concepts in hepatocellular carcinoma. Zentralbl Chir 125(7):647–649

    CAS  PubMed  Google Scholar 

  • Bosch FX, Ribes J, Diaz M, Cleries R (2004) Primary liver cancer: worldwide incidence and trends. Gastroenterology 127(5 suppl 1):S5–S16

    Article  PubMed  Google Scholar 

  • Cha CH, Ruo L, Fong Y, Jarnagin WR, Shia J, Blumgart LH et al (2003) Resection of hepatocellular carcinoma in patients otherwise eligible for transplantation. Ann Surg 238(3):315–321; discussion 321–323

    Google Scholar 

  • Chan KT, Lung ML (2004) Mutant p53 expression enhances drug resistance in a hepatocellular carcinoma cell line. Cancer Chemother Pharmacol 53(6):519–526

    Article  CAS  PubMed  Google Scholar 

  • Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ et al (2006) A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 243(3):321–328

    Article  PubMed  Google Scholar 

  • Cho CS, Gonen M, Shia J, Kattan MW, Klimstra DS, Jarnagin WR et al (2008) A novel prognostic nomogram is more accurate than conventional staging systems for predicting survival after resection of hepatocellular carcinoma. J Am Coll Surg 206(2):281–291

    Article  PubMed  Google Scholar 

  • Choi E, Rodgers S, Ahmad S, Abdalla E (2006) Hepatobiliary cancers. In: Feig B, Berger D, Fuhrman G (eds) The MD Anderson surgical oncology handbook. Lippincott Williams & Wilkins, Philadelphia, PA, pp 320–366

    Google Scholar 

  • Chu CM, Liaw YF (2006) Hepatitis B virus-related cirrhosis: natural history and treatment. Semin Liver Dis 26(2):142–152

    Article  CAS  PubMed  Google Scholar 

  • Clark HP, Carson WF, Kavanagh PV, Ho CP, Shen P, Zagoria RJ (2005) Staging and current treatment of hepatocellular carcinoma. Radiographics 25(suppl 1):S3–S23

    Article  PubMed  Google Scholar 

  • Cucchetti A, Ercolani G, Vivarelli M, Cescon M, Ravaioli M, La Barba G et al (2006) Impact of model for end-stage liver disease (MELD) score on prognosis after hepatectomy for hepatocellular carcinoma on cirrhosis. Liver Transpl 12(6):966–971

    Article  PubMed  Google Scholar 

  • Cunningham SC, Tsai S, Marques HP, Mira P, Cameron A, Barroso E et al (2009) Management of early hepatocellular carcinoma in patients with well-compensated cirrhosis. Ann Surg Oncol 16(7):1820–1831

    Article  PubMed  Google Scholar 

  • Del Gaudio M, Ercolani G, Ravaioli M, Cescon M, Lauro A, Vivarelli M et al (2008) Liver transplantation for recurrent hepatocellular carcinoma on cirrhosis after liver resection: University of Bologna experience. Am J Transplant 8(6):1177–1185

    Article  PubMed  Google Scholar 

  • Elbekai RH, Korashy HM, El-Kadi AO (2004) The effect of liver cirrhosis on the regulation and expression of drug metabolizing enzymes. Curr Drug Metab 5(2):157–167

    Article  CAS  PubMed  Google Scholar 

  • El-Serag HB (2002) Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 36(5 suppl 1):S74–S83

    Article  PubMed  Google Scholar 

  • El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132(7):2557–2576

    Article  CAS  PubMed  Google Scholar 

  • El-Serag HB, Hampel H, Javadi F (2006) The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 4(3):369–380

    Article  PubMed  Google Scholar 

  • Facciuto ME, Koneru B, Rocca JP, Wolf DC, Kim-Schluger L, Visintainer P et al (2008) Surgical treatment of hepatocellular carcinoma beyond Milan criteria. Results of liver resection, salvage transplantation, and primary liver transplantation. Ann Surg Oncol 15(5):1383–1391

    Article  PubMed  Google Scholar 

  • Fan ST, Lo CM, Liu CL, Lam CM, Yuen WK, Yeung C et al (1999) Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. Ann Surg 229(3):322–330

    Article  CAS  PubMed  Google Scholar 

  • Fausto N (1991) Growth factors in liver development, regeneration and carcinogenesis. Prog Growth Factor Res 3(3):219–234

    Article  CAS  PubMed  Google Scholar 

  • Feng DY, Zheng H, Tan Y, Cheng RX (2001) Effect of phosphorylation of MAPK and Stat3 and expression of c-fos and c-jun proteins on hepatocarcinogenesis and their clinical significance. World J Gastroenterol 7(1):33–36

    CAS  PubMed  Google Scholar 

  • Gambarin-Gelwan M, Wolf DC, Shapiro R, Schwartz ME, Min AD (2000) Sensitivity of commonly available screening tests in detecting hepatocellular carcinoma in cirrhotic patients undergoing liver transplantation. Am J Gastroenterol 95(6):1535–1538

    Article  CAS  PubMed  Google Scholar 

  • Gish RG, Porta C, Lazar L, Ruff P, Feld R, Croitoru A et al (2007) Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol 25(21):3069–3075

    Article  CAS  PubMed  Google Scholar 

  • Hino O, Kajino K, Umeda T, Arakawa Y (2002) Understanding the hypercarcinogenic state in chronic hepatitis: a clue to the prevention of human hepatocellular carcinoma. J Gastroenterol 37(11):883–887

    Article  CAS  PubMed  Google Scholar 

  • Hisaka T, Yano H, Haramaki M, Utsunomiya I, Kojiro M (1999) Expressions of epidermal growth factor family and its receptor in hepatocellular carcinoma cell lines: relationship to cell proliferation. Int J Oncol 14(3):453–460

    CAS  PubMed  Google Scholar 

  • Hong SN, Lee SY, Choi MS, Lee JH, Koh KC, Paik SW et al (2005) Comparing the outcomes of radiofrequency ablation and surgery in patients with a single small hepatocellular carcinoma and well-preserved hepatic function. J Clin Gastroenterol 39(3):247–252

    Article  PubMed  Google Scholar 

  • Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F et al (1995) Histological grading and staging of chronic hepatitis. J Hepatol 22:696–699

    Article  CAS  PubMed  Google Scholar 

  • Ito Y, Sasaki Y, Horimoto M, Wada S, Tanaka Y, Kasahara A et al (1998) Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma. Hepatology 27(4):951–958

    Article  CAS  PubMed  Google Scholar 

  • Izumi R, Shimizu K, Ii T, Yagi M, Matsui O, Nonomura A et al (1994) Prognostic factors of hepatocellular carcinoma in patients undergoing hepatic resection. Gastroenterology 106(3):720–727

    CAS  PubMed  Google Scholar 

  • Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E et al (2004) Cancer statistics, 2004. CA Cancer J Clin 54(1):8–29

    Article  PubMed  Google Scholar 

  • Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A et al (2005) Cancer statistics, 2005. CA Cancer J Clin 55(1):10–30

    Article  PubMed  Google Scholar 

  • Katz SC, Shia J, Liau KH, Gonen M, Ruo L, Jarnagin WR et al (2009) Operative blood loss independently predicts recurrence and survival after resection of hepatocellular carcinoma. Ann Surg 249(4):617–623

    Article  PubMed  Google Scholar 

  • Kim RD, Hemming AW (2009) Hepatocellular carcinoma: resection or transplantation. J Gastrointest Surg 13(6):1023–1025

    Article  PubMed  Google Scholar 

  • Kitamura T, Ichikawa T, Erturk SM, Nakajima H, Sou H, Araki T et al (2008) Detection of hypervascular hepatocellular carcinoma with multidetector-row CT: single arterial-phase imaging with computer-assisted automatic bolus-tracking technique compared with double arterial-phase imaging. J Comput Assist Tomogr 32(5):724–729

    Article  PubMed  Google Scholar 

  • Leung TW, Tang AM, Zee B, Lau WY, Lai PB, Leung KL et al (2002) Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer 94(6):1760–1769

    Article  PubMed  Google Scholar 

  • Li XM, Tang ZY, Qin LX, Zhou J, Sun HC (1999) Serum vascular endothelial growth factor is a predictor of invasion and metastasis in hepatocellular carcinoma. J Exp Clin Cancer Res 18(4):511–517

    CAS  PubMed  Google Scholar 

  • Liao AH, Cheng YC, Weng CH, Tsai TF, Lin WH, Yeh SH et al (2008) Characterization of malignant focal liver lesions with contrast-enhanced 40 MHz ultrasound imaging in hepatitis B virus X transgenic mice: a feasibility study. Ultrason Imaging 30(4):203–216

    PubMed  Google Scholar 

  • Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC (2005) Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 54(8):1151–1156

    Article  CAS  PubMed  Google Scholar 

  • Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D et al (2006) Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66(24):11851–11858

    Article  CAS  PubMed  Google Scholar 

  • Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L, Gazelle GS (1999) Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology 210(3):655–661

    CAS  PubMed  Google Scholar 

  • Llovet JM, Bru C, Bruix J (1999a) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19(3):329–338

    Article  CAS  PubMed  Google Scholar 

  • Llovet JM, Fuster J, Bruix J (1999b) Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 30(6):1434–1440

    Article  CAS  PubMed  Google Scholar 

  • Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J et al (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial [see comment]. Lancet 359(9319):1734–1739

    Article  PubMed  Google Scholar 

  • Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378–390

    Article  CAS  PubMed  Google Scholar 

  • Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT et al (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35(5):1164–1171

    Article  CAS  PubMed  Google Scholar 

  • Lo CM, Fan ST, Liu CL, Chan SC, Ng IO, Wong J (2007) Living donor versus deceased donor liver transplantation for early irresectable hepatocellular carcinoma. Br J Surg 94(1):78–86

    Article  CAS  PubMed  Google Scholar 

  • Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F et al (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334(11):693–699

    Article  CAS  PubMed  Google Scholar 

  • McKillop IH, Schmidt CM, Cahill PA, Sitzmann JV (1997) Altered expression of mitogen-activated protein kinases in a rat model of experimental hepatocellular carcinoma. Hepatology 26(6):1484–1491

    Article  CAS  PubMed  Google Scholar 

  • Mok TS, Wong H, Zee B, Yu KH, Leung TW, Lee TW et al (2002) A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma. Cancer 95(7):1511–1519

    Article  CAS  PubMed  Google Scholar 

  • Nakamura S, Nouso K, Sakaguchi K, Ito YM, Ohashi Y, Kobayashi Y et al (2006) Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Am J Gastroenterol 101(9):2038–2043

    Article  CAS  PubMed  Google Scholar 

  • Nathan H, Schulick RD, Choti MA, Pawlik TM (2009) Predictors of survival after resection of early hepatocellular carcinoma. Ann Surg 249(5):799–805

    Article  PubMed  Google Scholar 

  • Ng KK, Vauthey JN, Pawlik TM, Lauwers GY, Regimbeau JM, Belghiti J et al (2005) Is hepatic resection for large or multinodular hepatocellular carcinoma justified? Results from a multi-institutional database. Ann Surg Oncol 12(5):364–373

    Article  PubMed  Google Scholar 

  • (2002) NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 19(3):1–46

    Google Scholar 

  • Nissen NN, Martin P (2002) Hepatocellular carcinoma: the high-risk patient. J Clin Gastroenterol 35(5 suppl 2):S79–S85

    Article  CAS  PubMed  Google Scholar 

  • O’Dwyer PJ, Giantonio BJ, Levy DE, Kauh JS, Fitzgerald DB, Benson AB (2006) Gefitinib in advanced unresectable hepatocellular carcinoma: Results from the Eastern Cooperative Oncology Group’s Study E1203. J Clin Oncol 24:4143

    Article  Google Scholar 

  • Oh KC, Park SH, Park JC, Jin DK, Park CS, Kim KO et al (2005) Is the prevalence of cryptogenic hepatocellular carcinoma increasing in Korea? Korean J Gastroenterol 45(1):45–51

    PubMed  Google Scholar 

  • Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H et al (1985) Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 56(4):918–928

    Article  CAS  PubMed  Google Scholar 

  • Palavecino M, Chun YS, Madoff DC, Zorzi D, Kishi Y, Kaseb AO et al (2009) Major hepatic resection for hepatocellular carcinoma with or without portal vein embolization: perioperative outcome and survival. Surgery 145(4):399–405

    Article  PubMed  Google Scholar 

  • Pastorelli D, Cartei G, Zustovich F, Marchese F, Artioli G, Zovato S et al (2006) Gemcitabine and liposomal doxorubicin in biliary and hepatic carcinoma (HCC) chemotherapy: preliminary results and review of the literature. Ann Oncol 17(suppl 5):v153–v157

    Article  PubMed  Google Scholar 

  • Patt YZ, Hassan MM, Lozano RD, Nooka AK, Schnirer II, Zeldis JB et al (2005) Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial. Cancer 103(4):749–755

    Article  CAS  PubMed  Google Scholar 

  • Pawlik TM (2009) Debate: resection for early hepatocellular carcinoma. J Gastrointest Surg 13(6):1026–1028

    Article  PubMed  Google Scholar 

  • Pawlik TM, Poon RT, Abdalla EK, Zorzi D, Ikai I, Curley SA et al (2005a) Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. Arch Surg 140(5):450–457; discussion 457–458

    Google Scholar 

  • Pawlik TM, Delman KA, Vauthey JN, Nagorney DM, Ng IO, Ikai I et al (2005b) Tumor size predicts vascular invasion and histologic grade: implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl 11(9):1086–1092

    Article  PubMed  Google Scholar 

  • Pawlik TM, Poon RT, Abdalla EK, Ikai I, Nagorney DM, Belghiti J et al (2005c) Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: results of a multicenter study. Surgery 137(4):403–410

    Article  PubMed  Google Scholar 

  • Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G et al (2005) Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 23(27):6657–6663

    Article  CAS  PubMed  Google Scholar 

  • Poon RT, Fan ST, Lo CM, Liu CL, Wong J (2002) Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg 235(3):373–382

    Article  PubMed  Google Scholar 

  • The Cancer of the Liver Italian Program (CLIP) Investigators (2000) Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 31(4):840–845

    Article  Google Scholar 

  • Ringe B, Pichlmayr R, Wittekind C, Tusch G (1991) Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients. World J Surg 15(2):270–285

    Article  CAS  PubMed  Google Scholar 

  • Sahin F, Kannangai R, Adegbola O, Wang J, Su G, Torbenson M (2004) mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res 10(24):8421–8425

    Article  CAS  PubMed  Google Scholar 

  • Sassa T, Kumada T, Nakano S, Uematsu T (1999) Clinical utility of simultaneous measurement of serum high-sensitivity des-gamma-carboxy prothrombin and Lens culinaris agglutinin A-reactive alpha-fetoprotein in patients with small hepatocellular carcinoma. Eur J Gastroenterol Hepatol 11(12):1387–1392

    Article  CAS  PubMed  Google Scholar 

  • Secil M, Obuz F, Altay C, Gencel O, Igci E, Sagol O et al (2008) The role of dynamic subtraction MRI in detection of hepatocellular carcinoma. Diagn Interv Radiol 14(4):200–204

    PubMed  Google Scholar 

  • Shah SA, Cleary SP, Tan JC, Wei AC, Gallinger S, Grant DR et al (2007) An analysis of resection vs transplantation for early hepatocellular carcinoma: defining the optimal therapy at a single institution. Ann Surg Oncol 14(9):2608–2614

    Article  PubMed  Google Scholar 

  • Shinmura R, Matsui O, Kadoya M, Kobayashi S, Terayama N, Sanada J et al (2008) Detection of hypervascular malignant foci in borderline lesions of hepatocellular carcinoma: comparison of dynamic multi-detector row CT, dynamic MR imaging and superparamagnetic iron oxide-enhanced MR imaging. Eur Radiol 18(9):1918–1924

    Article  PubMed  Google Scholar 

  • Silva M, Moya A, Berenguer M, Sanjuan F, Lopez-Andujar R, Pareja E et al (2008) Expanded criteria for liver transplantation in patients with cirrhosis and hepatocellular carcinoma. Liver Transpl 14(10):1449–1460

    Article  PubMed  Google Scholar 

  • Simonetti RG, Liberati A, Angiolini C, Pagliaro L (1997) Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann Oncol 8(2):117–136

    Article  CAS  PubMed  Google Scholar 

  • Smedile A, Bugianesi E (2005) Steatosis and hepatocellular carcinoma risk. Eur Rev Med Pharmacol Sci 9(5):291–293

    CAS  PubMed  Google Scholar 

  • Sun W, Haller DG, Mykulowycz K, Rosen M, Soulen M, Capparo M et al (2007) Combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma (HCC): A phase II study. J Clin Oncol 25(18):4574

    Google Scholar 

  • Takada Y, Ito T, Ueda M, Sakamoto S, Haga H, Maetani Y et al (2007) Living donor liver transplantation for patients with HCC exceeding the Milan criteria: a proposal of expanded criteria. Dig Dis 25(4):299–302

    Article  PubMed  Google Scholar 

  • Tam KH, Yang ZF, Lau CK, Lam CT, Pang RW, Poon RT (2009) Inhibition of mTOR enhances chemosensitivity in hepatocellular carcinoma. Cancer Lett 273(2):201–209

    Article  CAS  PubMed  Google Scholar 

  • Teh SH, Christein J, Donohue J, Que F, Kendrick M, Farnell M et al (2005) Hepatic resection of hepatocellular carcinoma in patients with cirrhosis: Model of End-Stage Liver Disease (MELD) score predicts perioperative mortality. J Gastrointest Surg 9(9):1207–1215; discussion 1215

    Google Scholar 

  • Thomas MB, Chadha R, Glover K, Wang X, Morris J, Brown T et al (2007) Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 110(5):1059–1067

    Article  CAS  PubMed  Google Scholar 

  • Thomas MB, Morris JS, Chadha R, Iwasaki M, Kaur H, Lin E et al (2009) Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 27(6):843–850

    Article  CAS  PubMed  Google Scholar 

  • Todo S, Furukawa H; Japanese Study Group on Organ T (2004) Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. Ann Surg 240(3):451–459; discussion 459–461

    Google Scholar 

  • Treiber G (2009) mTOR inhibitors for hepatocellular cancer: a forward-moving target. Expert Rev Anticancer Ther 9(2):247–261

    Article  CAS  PubMed  Google Scholar 

  • Tu R, Xia LP, Yu AL, Wu L (2007) Assessment of hepatic functional reserve by cirrhosis grading and liver volume measurement using CT. World J Gastroenterol 13(29):3956–3961

    PubMed  Google Scholar 

  • Vauthey JN, Lauwers GY, Esnaola NF, Do KA, Belghiti J, Mirza N et al (2002) Simplified staging for hepatocellular carcinoma. J Clin Oncol 20(6):1527–1536

    Article  PubMed  Google Scholar 

  • Villanueva A, Chiang DY, Newell P, Peix J, Thung S, Alsinet C et al (1983) Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 135(6):1972–1983

    Article  Google Scholar 

  • Watanuki A, Ohwada S, Fukusato T, Makita F, Yamada T, Kikuchi A et al (2002) Prognostic significance of DNA topoisomerase IIalpha expression in human hepatocellular carcinoma. Anticancer Res 22(2B):1113–1119

    CAS  PubMed  Google Scholar 

  • Yamaguchi R, Yano H, Nakashima O, Akiba J, Nishida N, Kurogi M et al (2006) Expression of vascular endothelial growth factor-C in human hepatocellular carcinoma. J Gastroenterol Hepatol 21(1 pt 1):152–160

    Article  CAS  PubMed  Google Scholar 

  • Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A et al (2001) Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 33(6):1394–1403

    Article  CAS  PubMed  Google Scholar 

  • Yao FY, Bass NM, Nikolai B, Davern TJ, Kerlan R, Wu V et al (2002) Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl 8(10):873–883

    Article  PubMed  Google Scholar 

  • Yeo W, Mok TS, Zee B, Leung TW, Lai PB, Lau WY et al (2005) A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 97(20):1532–1538

    Article  CAS  PubMed  Google Scholar 

  • Zhu AX, Blaszkowsky LS, Ryan DP, Clark JW, Muzikansky A, Horgan K et al (2006) Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 24(12):1898–1903

    Article  CAS  PubMed  Google Scholar 

  • Zhu AX, Stuart K, Blaszkowsky LS, Muzikansky A, Reitberg DP, Clark JW et al (2007) Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer 110(3):581–589

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hollings Cancer Center, A National Cancer Institute Designated Cancer Center, Medical University of South Carolina, 86 Jonathan Lucas Street, Charleston, SC, 29425, USA

    Joseph D. Thomas, George A. Poultsides, Timothy M. Pawlick & Melanie B. Thomas

Authors
  1. Joseph D. Thomas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. George A. Poultsides
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Timothy M. Pawlick
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Melanie B. Thomas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Melanie B. Thomas .

Editor information

Editors and Affiliations

  1. Div. Medical Oncology, University of British Columbia, West 10th Avenue 600, Vancouver, V5Z 4E6, British Columbia, Canada

    Charles D. Blanke

  2. FB 19 Zentrum der Radiologie, Klinik f. Strahlentherapie, Universitätsklinikum Frankfurt, Theodor-Stern-Kai 7, Frankfurt, 60590, Germany

    Claus Rödel

  3. Evanston Northwestern Healthcare, Northwestern University, Ridge Ave. 2650, Evanston, 60201, Illinois, USA

    Mark S. Talamonti

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Berlin Heidelberg

About this chapter

Cite this chapter

Thomas, J.D., Poultsides, G.A., Pawlick, T.M., Thomas, M.B. (2011). Liver Cancer. In: Blanke, C., Rödel, C., Talamonti, M. (eds) Gastrointestinal Oncology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-13306-0_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-13306-0_9

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-13305-3

  • Online ISBN: 978-3-642-13306-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation